In particular, HNF1A maturity-onset diabetes of the young (MODY) is very amenable to therapy with sulfonylureas, whereas, for GCK MODY, no pharmacological treatment is recommended, and diet and regular physical activity are necessary to maintain good glycemic control [140]. Here, HNF1A is linked to MODY.